Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report.

Moisset L, Raimbourg J, Hiret S, Dauve J, Boisdron-Celle M, Senellart H, Raoul JL.

Case Rep Oncol. 2019 Jun 5;12(2):426-429. doi: 10.1159/000500857. eCollection 2019 May-Aug.

2.

Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method.

Boisdron-Celle M, Metges J, Capitain O, Faroux R, Stampfli C, Ferec M, Laplaige P, Lecomte T, Matysiak-Budnik T, Senellart H, Campone M, Morel A, Gamelin E.

Ann Oncol. 2018 Jun;29 Suppl 5:v60-v61. doi: 10.1093/annonc/mdy151.215. Epub 2020 Jan 7. No abstract available.

3.

In reply.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Philippe Metges J, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Apr;44(2):161. doi: 10.1053/j.seminoncol.2017.08.002. Epub 2017 Aug 4. No abstract available.

PMID:
28923216
4.

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.

Boisdron-Celle M, Metges JP, Capitain O, Adenis A, Raoul JL, Lecomte T, Lam YH, Faroux R, Masliah C, Poirier AL, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Feb;44(1):24-33. doi: 10.1053/j.seminoncol.2017.02.007. Epub 2017 Feb 9.

PMID:
28395759
5.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Feb;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. Epub 2017 Feb 11.

PMID:
28395758
6.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.

Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T.

Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30.

PMID:
26615857
7.

In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps.

Dupoiron D, Richard H, Chabert-Desnot V, Devys C, Leynia P, Boisdron-Celle M.

Neuromodulation. 2014 Jul;17(5):472-82; discussion 482. doi: 10.1111/ner.12142. Epub 2014 Feb 11.

PMID:
24512055
8.

[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].

Rieux C, Boisdron-Celle M, Morel A, Fey L, Urban T, Hureaux J.

Rev Mal Respir. 2013 Sep;30(7):572-5. doi: 10.1016/j.rmr.2013.02.010. Epub 2013 Mar 26. French.

PMID:
24034463
9.

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.

Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, Ohresser M, Boisdron-Celle M, Gamelin E, Watier H, Paintaud G, Gouilleux-Gruart V.

MAbs. 2013 Jul-Aug;5(4):614-9. doi: 10.4161/mabs.24815. Epub 2013 Apr 25.

10.

Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?

Boisdron-Celle M.

Pharmacogenomics. 2012 Oct;13(13):1437-9. doi: 10.2217/pgs.12.132. No abstract available.

11.

Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.

Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E.

Clin Colorectal Cancer. 2012 Dec;11(4):263-7. doi: 10.1016/j.clcc.2012.05.004. Epub 2012 Jun 9.

PMID:
22683364
12.

A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.

Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, Solassol J, Campone M, Gamelin E, Barré B, Coqueret O, Guette C.

Mol Cell Proteomics. 2011 Dec;10(12):M111.009712. doi: 10.1074/mcp.M111.009712. Epub 2011 Oct 10.

13.

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.

Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.

Clin Cancer Res. 2011 Oct 1;17(19):6329-37. doi: 10.1158/1078-0432.CCR-11-1081. Epub 2011 Sep 27.

14.

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

Basseville A, Preisser L, de Carné Trécesson S, Boisdron-Celle M, Gamelin E, Coqueret O, Morel A.

Mol Cancer. 2011 Jul 6;10:80. doi: 10.1186/1476-4598-10-80.

15.

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.

Cellier P, Leduc B, Martin L, Vié B, Chevelle C, Vendrely V, Salemkour A, Carrie C, Calais G, Burtin P, Campion L, Boisdron-Celle M, Morel A, Berger V, Gamelin E.

BMC Cancer. 2011 Mar 16;11:98. doi: 10.1186/1471-2407-11-98.

16.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E.

J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20.

PMID:
20855828
17.

[Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols].

Boisdron-Celle M, Le Guellec C; Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.

Therapie. 2010 May-Jun;65(3):171-6. doi: 10.2515/therapie/2010023. Epub 2010 Aug 11. Review. French.

PMID:
20699067
18.

Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.

Mounier-Boutoille H, Boisdron-Celle M, Cauchin E, Galmiche JP, Morel A, Gamelin E, Matysiak-Budnik T.

Br J Clin Pharmacol. 2010 Aug;70(2):280-3. doi: 10.1111/j.1365-2125.2010.03686.x. No abstract available.

19.

Niveau de preuve du suivi thérapeutique pharmacologique du 5-fluorouracile au décours de son administration dans le traitement des cancers des voies aérodigestives supérieures et du cancer colorectal.

Boisdron-Celle M, Le Guellec C; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.

Therapie. 2010 May-Jun;65(3):171-6. doi: 10.2515/therapie/2010023. French.

PMID:
27392983
20.

[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].

Boisdron-Celle M, Morel A, Gamelin E.

Ann Biol Clin (Paris). 2010 Jan-Feb;68(1):27-32. doi: 10.1684/abc.2010.0394. Review. French.

21.

Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer.

Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, Harney RL, Hammett-Stabler C, Lepp S, Li Y, Lundell GD, McMillin G, Milano G, Salamone SJ.

Ther Drug Monit. 2009 Dec;31(6):688-94. doi: 10.1519/JSC.0b013e3181b866d0.

PMID:
19935361
22.

A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.

Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E.

Clin Cancer Res. 2009 May 15;15(10):3633-9. doi: 10.1158/1078-0432.CCR-09-0017. Epub 2009 Apr 28.

23.

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.

Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J, Gamelin E.

Br J Cancer. 2008 Oct 21;99(8):1239-45. doi: 10.1038/sj.bjc.6604673. Epub 2008 Sep 16.

24.

Aerosolized chemotherapy.

Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lemarie E.

J Aerosol Med Pulm Drug Deliv. 2008 Mar;21(1):61-70. doi: 10.1089/jamp.2007.0656. Review.

PMID:
18518832
25.

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M.

J Clin Oncol. 2008 May 1;26(13):2099-105. doi: 10.1200/JCO.2007.13.3934. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612.

PMID:
18445839
26.

Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.

Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A.

J Clin Oncol. 2008 Mar 1;26(7):1188-9; author reply 1189-90. doi: 10.1200/JCO.2007.15.3767. No abstract available.

PMID:
18309961
27.

A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.

Blasco H, Boisdron-Celle M, Bougnoux P, Calais G, Tournamille JF, Ciccolini J, Autret-Leca E, Le Guellec C.

Br J Clin Pharmacol. 2008 Jun;65(6):966-70. doi: 10.1111/j.1365-2125.2008.03106.x. Epub 2008 Feb 20. No abstract available.

28.

[Pharmacogenetics of anti-cancer drugs].

Gamelin E, Boisdron-Celle M, Morel A, Capitain O.

Ann Pharm Fr. 2007 Nov;65(6):390-401. Review. French.

PMID:
18079671
29.

[Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects].

Allorge D, Beaune PH, Becquemont L, Bessard G, Bezieau S, Boisdron-Celle M, Boyer JC, Broly F, Dhaneens CM, Fonrose X, Gagnieu MC, Gamelin E, Gozé C, Jacqz-Aigrain E, Loric S, Loriot MA, Marquet P, Morel A, Namour B, Paintaud G, Peoc'h K, Picard N, Watier H, Verstuyft C.

Ann Pharm Fr. 2007 Nov;65(6):371-81. Review. French.

PMID:
18079669
30.

Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway.

Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, Gilles S, Boisdron-Celle M, Gamelin E.

Clin Cancer Res. 2007 Nov 1;13(21):6359-68.

31.

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.

Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E.

Pharmacogenomics J. 2008 Aug;8(4):256-67. Epub 2007 Aug 14.

PMID:
17700593
32.

[Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].

Gamelin E, Boisdron-Celle M, Morel A.

Therapie. 2007 Mar-Apr;62(2):99-103. Epub 2007 Jun 21. French.

PMID:
17582309
33.

Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.

Beneton M, Chapet S, Blasco H, Giraudeau B, Boisdron-Celle M, Deporte-Fety R, Denis F, Narcisso B, Calais G, Le Guellec C.

Br J Clin Pharmacol. 2007 Nov;64(5):613-21. Epub 2007 Jun 19.

34.

Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.

Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, Gamelin E.

Mol Cancer Ther. 2006 Nov;5(11):2895-904.

35.

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.

Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E.

Cancer Lett. 2007 May 8;249(2):271-82. Epub 2006 Oct 24.

PMID:
17064846
37.

Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.

Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, Joly F, Chieze S, Chabrun V, Gamelin E, Tourani JM.

Am J Clin Oncol. 2006 Jun;29(3):267-75.

PMID:
16755180
38.

[Oxaliplatin neurotoxicity].

Gamelin L, Boisdron-Celle M, Morel A, Gamelin E.

Bull Cancer. 2006 Feb 1;93 Suppl 1:S17-22. Review. French.

PMID:
16491518
39.

Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype.

Barbado M, Preisser L, Boisdron-Celle M, Verriele V, Lorimier G, Gamelin E, Morel A.

Cancer Lett. 2006 Oct 28;242(2):168-79. Epub 2006 Jan 4.

40.

Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons.

Gagnadoux F, Leblond V, Vecellio L, Hureaux J, Le Pape A, Boisdron-Celle M, Montharu J, Majoral C, Fournier J, Urban T, Diot P, Racineux JL, Lemarié E.

Cancer Chemother Pharmacol. 2006 Aug;58(2):237-44. Epub 2005 Nov 19.

PMID:
16328414
41.

Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma.

Remaud G, Boisdron-Celle M, Morel A, Gamelin A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):153-60.

PMID:
16061432
42.

An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.

Remaud G, Boisdron-Celle M, Hameline C, Morel A, Gamelin E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 5;823(2):98-107.

PMID:
16027050
43.

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.

Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A, Gamelin E.

Clin Cancer Res. 2004 Aug 1;10(15):5151-9.

44.
45.

Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma.

Menei P, Jadaud E, Faisant N, Boisdron-Celle M, Michalak S, Fournier D, Delhaye M, Benoit JP.

Cancer. 2004 Jan 15;100(2):405-10.

47.

Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.

Boisdron-Celle M, Craipeau C, Brienza S, Delva R, Guérin-Meyer V, Cvitkovic E, Gamelin E.

Cancer Chemother Pharmacol. 2002 Mar;49(3):235-43. Epub 2002 Jan 16.

PMID:
11935216
48.

[Pharmacokinetic properties of platinium derivatives].

Boisdron-Celle M, Lebouil A, Allain P, Gamelin E.

Bull Cancer. 2001 Aug;88 Spec No:S14-9. Review. French.

PMID:
11567909
49.

Experimental assessment of tumor growth and dissemination of a microscopic peritoneal carcinomatosis after CO2 peritoneal insufflation or laparotomy.

Fondrinier E, Boisdron-Celle M, Chassevent A, Lorimier G, Gamelin E.

Surg Endosc. 2001 Aug;15(8):843-8. Epub 2001 May 7.

PMID:
11443420
50.

A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.

Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E.

J Neurophysiol. 2001 May;85(5):2293-7.

Supplemental Content

Loading ...
Support Center